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48Background: Signal Transducer and Activator of Transcription 1 (STAT1) Gain of Function (GoF) mutations
can predispose to chronic mucocutaneous candidiasis (CMC). Long term therapy with oral azole antifun-
gals can result in resistance and the need to treat with alternatives such as echinocandins.
Case Report: A pan-azole-resistant Candida albicans was isolated from a mouth swab from a 39-year-old
woman with lifelong CMC. Her condition warranted systemic treatment and this was achieved through
daily infusions of micafungin, which the patient self-administered at home within the OPAT (Outpatient
Parenteral Antimicrobial Therapy) service. The patient experienced a good and rapid clinical response. On
day 18 of treatment the patient developed an itchy rash and presented back to our hospital on day 22. A
diagnosis of phototoxic skin reaction, secondary to micafungin, was established through clinical history,
signs, and investigations.
Results: Micafungin was withdrawn and the phototoxic reaction resolved without further intervention.
The patient was maintained on amphotericin oral lozenges.
Conclusion: More research into the phototoxic potential of micafungin and its metabolites is needed but
clinicians should remain aware of the potential of phototoxicity in individuals treated in outpatient and
OPAT settings.
 2020 Published by Elsevier Ltd on behalf of British Infection Association. This is an open access article
















Autosomal dominant Signal Transducer and Activator of Tran-
scription 1 (STAT1) Gain of Function (GoF) mutations are recog-
nised as the most common monogenic cause of chronic
mucocutaneous candidiasis (CMC) since their identification in
2011. STAT1 is a second messenger within the JAK-STAT pathway
and in GoF mutations there is increased STAT1 phosphorylation
which drives a skewed immune response (Zheng et al., 2015). They
have a wide clinical spectrum from pure mucocutaneous candidia-
sis with or without autoimmune disease through to a severe
immunodeficiency with enteropathy. Increased candidiasis, which
is often difficult to treat, is likely due to impaired Th17 responses
(Firinu et al., 2011).
Oral azole antifungals, such as fluconazole, itraconazole, and
voriconazole are generally recommended as the first-line agents82
83
84
85for non-genital mucocutaneous candidiasis and CMC (Pappas
et al., 2004). Azole-resistant isolates of Candida have been
observed in patients with CMC secondary to STAT1-GoF treated
with prolonged courses of tri-azole antifungals (Humbert et al.,
2018). In the UK, micafungin is licensed in adults for i) treatment
of invasive candidiasis, ii) treatment of oesophageal candidiasis
in patients for whom IV therapy is appropriate, and iii) prophylaxis
against Candida infection in those undergoing allogeneic
haematopoietic stem cell transplantation or who are expected to
have neutropenia for 10 days or more (MHRA, 2019). Therefore,
micafungin would be a reasonable second-line option in cases of
azole-resistance or other contraindications in patients with CMC.
Micafungin is a semi-synthetic lipopeptide belonging to the
echinocandin class that selectively inhibits the formation of 1,3-
b-D-glucan, which is a vital component of the fungal cell-wall, thus
resulting in cell lysis (Wasmann et al., 2017). Micafungin dis-
tributes widely into tissues and achieves therapeutic concentra-
tions in skin-structures, lung tissue and peritoneal fluid, but
penetration into the CSF is limited (Felton et al., 2014; Yamada
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CMC who has a novel pathogenic mutation in STAT1 and experi-






















































Before referral to immunology, the patient had experienced per-
sistent oral candidiasis for many years, managed in primary care
with repeated courses of fluconazole and itraconazole. The
patient’s mother had the same symptoms, but died of ‘throat’ can-
cer aged 53. The patient’s 7-year-old daughter has the same muta-
tion but remains asymptomatic at the time of this report. Her
dentition was very poor due to dental phobia and smoking tobacco.
Repeated HIV testing was negative and she had no other symptoms
attributable to her STAT1-GoF; no inflammatory bowel disease,
negative autoantibodies to endocrine organs, negative ANA, nor-
mal total immunoglobulins and normal T, NK and B cell numbers.
On diagnosis of STAT1-GoF, mouth swabs in September 2018
and June 2019 isolated Candida albicans with pan-azole resistance
but susceptibility to amphotericin, echinocandins and flucytosine.
Severe oral discomfort from oral candidiasis and a painful swallow,
suggesting oesophageal involvement, led to a referral to the Outpa-
tient Parenteral Antimicrobial Therapy (OPAT) service for consider-
ation of parenteral antifungals.
Intravenous micafungin 150 mg once daily, as per the UK
license for managing oesophageal candidiasis, for an initial period
of fourteen days was commenced in April 2019. After training by
the OPAT specialist nurses, the patient self-administered mica-
fungin at home via a midline. By day 8 her symptoms were much
improved, with some mild residual soreness of the throat. On
examination the mouth was still slightly inflamed but only one
to two white plaques in the mouth were visible. On day 15 there
was no odynophagia and the mouth appeared clear. On advice
from regional experts, treatment was extended by seven further
days to reduce the risk of early relapse, particularly given the lack
of oral alternatives.
On day 22, the patient attended routine end-of-treatment
follow-up with a rash. This had started four days’ previously as
uncomfortable non-itchy ‘‘bumps”. The weather having been warm
and bright, she had been wearing a t-shirt with thin shoulder-
straps and trousers ending at her mid-calf. The rash was only evi-
dent on skin-exposed areas over her upper chest, shoulders, arms
and ankles. There was sparing of the face, which the patient attrib-
uted to her makeup providing high levels of UV protection. At
review, the rash had progressed to a confluent erythematous rash
and the skin appeared slightly oedematous with mild pitting over
the distal tibiae. Eosinophil counts were not raised and hepatic and
renal function tests were normal.
Micafungin was immediately stopped. The patient did not
require hospital admission and the rash resolved spontaneously
after a few days. She has not had micafungin since, although a fur-
ther course is planned around the time of elective dental clearance
in 2020, when she will be advised to avoid exposure to direct sun-
light where possible, apply high sun protection factor (SPF) cream
to exposed areas, and ensure the micafungin infusion is protected
from light. The patient has been maintained on amphotericin
lozenges for oral symptoms, and terbinafine for Trychophyton iso-






This is the first case in the published literature to describe a
phototoxic skin reaction in an individual taking micafungin, and
is also the first reported case of such a reaction in an individual2
with STAT1-GoF mutation. Although our centre does undertake
phototoxicity testing, the case history and clear demarcation from
clothing and high-SPF makeup, and absence of other identifiable
causes suggest this phototoxic reaction was driven through expo-
sure to sunlight, rather than a generalised dermatological drug-
reaction to micafungin. The development of this reaction over a
number of days, its symptomatic description by the patient, and
the clinical findings also make differential causes such as sunburn,
heat rash, and generalised dermatological drug-reaction unlikely
causes. While skin reactions such as rashes, erythema, erythema
multiforme, and Stevens-Johnson Syndrome / Toxic Epidermal
Necrolysis (SJS/TEN) are highlighted within product literature
(MHRA, 2019), this is the first case in the medical and scientific lit-
erature of a phototoxic skin reaction to this drug, and is the first
case of this reaction to be reported to the UK’s Medicines and
Healthcare products Regulatory Agency (MHRA) Yellow Card
Scheme. Lack of reports of phototoxicity secondary to micafungin
may be due to it predominately being used within hospital set-
tings, where exposure to sunlight is less likely. Our patient was
ambulatory and self-administering micafungin within the OPAT
service, which allowed her to remain at home and live a near nor-
mal life and enjoy being outside in the warm and bright weather at
the time.
Absorption of UV-photons by drug-molecules can result in
structural changes, photolysis, and generation of reactive oxygen
species, which can cause dermal toxicity (Kim et al., 2015). Stabil-
ity studies undertaken during the micafungin licensing process
demonstrated up to 12.2% loss under a 3000 lx lamp, resulting in
advice within the product literature to protect the product and
infusions from UV light (CHMP, 2008). Subsequent studies identi-
fied approximately eleven break-down products that can arise
from UV-photolysis, hydrolysis, oxidation, and biologic metabo-
lism of micafungin (Zhu et al., 2013). Micafungin distributes widely
into most tissues (Vd 0.2 L/kg) and achieves therapeutic concentra-
tions in skin-structures (T/P ratio  0.46) (Yamada et al., 2011).
Within the skin and skin-structures it is likely to be exposed to
UV-light, within an aqueous and oxygenated environment,
enabling photolysis and the generation of a range of secondary
break-down molecules. The antifungal effects of some of these
metabolites have been demonstrated (Ikeda et al., 2002) and stan-
dard pharmacokinetic parameters have been defined in adults and
children for the two major metabolites M1 and M2 (Tabata et al.,
2006; Azuma et al., 2002). However, the phototoxic potential of
micafungin or its metabolites has not been specifically determined,
even though the majority of these molecules contain chro-
mophores. This case highlights the need to further characterise
the metabolites of micafungin and determine their potential for
phototoxicity.
It remains unclear whether STAT1-GoF or CMC can predispose
to photosensitivity, with only one other instance of photosensitiv-
ity of the skin and genital mucosa reported in a 3-month-old baby
with CMC but who was also ANA positive (Liu, 2013). Considering
how rare these conditions are and the infrequent use of micafungin
in the outpatient setting, an interplay between STAT1-Gof, CMC
and micafungin inducing phototoxicity cannot be completely
excluded.Conclusion
This is the first reported case of phototoxicity due to intra-
venous micafungin therapy. However, the ability of micafungin
and its metabolites to induce such phototoxicity requires further
investigation. Similarly, the role of STAT1-GoF and CMC in photo-
sensitivity also requires further research. Increasingly, patients
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16 December 2020their own homes (Durojaiye et al., 2019), so those administering
this drug must be reminded to protect the infusion from light
and clinicians should remain aware of the potential for phototoxi-
city. If future research proves micafungin can precipitate photo-
toxic reactions it will be necessary to advise patients to protect
themselves from sunlight by avoiding exposure where possible
or using high SPF creams.
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